Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the approval of its investigational new drug, SKB535, by the National Medical Products Administration for clinical trials. This innovative ADC drug, developed using the company’s OptiDC platform, aims to treat advanced solid tumors and has already shown promising results in preclinical studies. The company has partnered with Merck & Co., Inc. to further develop SKB535, offering potential milestone payments and royalties upon successful commercialization.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.